Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors
- Resource Type
- Article
- Source
- In
ESMO Open October 2022 7(5) - Subject
- Language
- ISSN
- 2059-7029